#USA #New York #Pomerantz Law Firm #SMMT #Summit Therapeutics

Investigation into Summit Therapeutics

The Pomerantz Law Firm is proactively investigating claims from investors of Summit Therapeutics Inc. (traded under the NASDAQ symbol SMMT). The firm’s investigation seeks to uncover whether the company and its executives have committed securities fraud or participated in any unlawful business practices. This inquiry aligns with the firm’s commitment to protecting the rights of investors, particularly in light of recent events surrounding Summit's Phase III clinical trial.

Clinical Trial Results and Stock Impact

On May 30, 2025, Summit Therapeutics publicized topline results from its Phase III clinical trial, known as HARMONi, which studied the efficacy of ivonescimab in combination with chemotherapy. Although the results indicated that patients who received ivonescimab combined treatment experienced a 48% reduction in the likelihood of progression or death compared to those on chemotherapy alone, the drug failed to demonstrate a statistically significant impact on overall survival.

This disappointing result prompted a significant fallout on the stock market, where Summit's share price plummeted by $7.99, translating to a 30.5% drop, closing at $18.22 per share on the same day.

What Should Investors Do?

Investors impacted by this decline and who believe they may have claims against Summit Therapeutics are encouraged to reach out to Pomerantz Law Firm for further assistance. Danielle Peyton, a representative of the firm, is available at [email protected] or can be contacted at 646-581-9980 extension 7980.

About Pomerantz Law Firm

Founded over 85 years ago by the esteemed Abraham L. Pomerantz, widely known as the father of class action litigation, Pomerantz LLP has built a noteworthy legacy in advocating for victims of securities fraud and corporate misconduct. With offices in major cities across the globe, including New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, the firm has successfully recovered millions of dollars on behalf of its clients.

Conclusion

As the investigation unfolds, it is essential for investors in Summit Therapeutics to stay informed about their rights and the legal proceedings that may arise from this situation.